Received Jun 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
VARIVAX and PROQUAD. AE was filed as both vaccines contained varicella component; intended to provide patient with VARIVAX and MMR II.; No symptomatic events reported; This spontaneous report was received from a nurse practitioner referring to a patient of unknown gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies, and concomitant therapies were not reported. On an unknown date, the patient was intended to receive varicella virus vaccine live (oka/merck)(VARIVAX) and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) for prophylaxis, but on 20-May-2025, was vaccinated with varicella virus vaccine live (oka/merck)(VARIVAX) and measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) (strengths, specific dosages, dose numbers, routes of administration, anatomical sites of application, lot numbers and expiration dates were not provided). AE was filed as both vaccines contained varicella component. No symptomatic events. Lot # is being requested and will be submitted if received.
Sterile diluent